TB-500
Thymosin Beta-4 fragment / TB-500
Healing & Tissue Repair
TB-500 is usually discussed in the context of tissue repair, mobility, inflammation signaling, and recovery-related mechanisms connected to thymosin beta-4 biology. Public claims often run ahead of the clinical evidence, so it should be treated as an evidence-limited research topic rather than an established recovery therapy.
Deep Dives on TB-500
Start here for the plain-English articles connected to this peptide.
FDA’s Peptide Compounding Policy Reached White House Review—What That Does (and Does Not) Change
FDA’s peptide compounding policy entered OIRA review in October 2026. Learn what Executive Order 12866 review means—and what it does not change.
Read articleThree Nerve-Injury Cases Do Not Prove BPC-157 or TB-500 Is Effective: How to Read a Multimodal Case Report
What three inferior alveolar nerve injury cases show—and why they do not prove BPC-157, TB-500, ARA-290, or the combination is effective.
Read articleBPC-157 Use Is Rising—Why 1,039 Clinical Notes Still Do Not Prove It Works
A 2026 preprint found 1,039 documented BPC-157 users and sharply rising use, but incomplete notes, co-treatments and an uncontrolled design cannot prove efficacy or safety.
Read articleCan a Frog Peptide Heal Skin Wounds? What the OL-RA11 Autophagy Study Actually Shows
A 2026 study linked OL-RA11 to macrophage autophagy, keratinocyte Wnt signaling, and faster wound repair in mice. The mechanism is coherent, but human efficacy and safety remain unknown.
Read articleCan a Self-Assembling Peptide Repair Tendons? What the Rat and Beagle Study Actually Shows
A 2026 study linked an engineered TGF-β1-capturing peptide to tendon repair measures in rats and beagles. Here is what the preclinical evidence does—and does not—show.
Read articleFDA Panel Backed Six Peptides for Compounding—What the Vote Does (and Does Not) Mean
The FDA advisory panel backed 503A Bulks List inclusion for the free-base and acetate forms of six peptide groups and rejected emideltide/DSIP. Here is what the non-binding vote means—and what it does not prove.
Read articlePeptides for Long COVID: What Is Being Studied—and What Is Only Being Marketed
No peptide is proven to treat Long COVID. Separate controlled trials of tirzepatide and larazotide from planned research, animal studies, anecdotes, and marketing.
Read articlePeptides in Real Medicine: PRRT, Edotreotide, and Neuroendocrine Tumor Evidence
What the phase 3 COMPETE trial of [177Lu]Lu-edotreotide versus everolimus teaches about peptide receptor radionuclide therapy, disease-specific evidence, and why regulated peptide medicines should not be confused with wellness peptide marketing.
Read articleFDA Research Peptide Compounding Review: What It Is and What It Is Not
A cautious explainer on FDA's July 2026 review of seven peptide-related bulk drug substances for the 503A Bulks List, why staff opposition matters, and why the review is not FDA approval or proof of safety.
Read articleIs Orforglipron a Peptide? The New Oral GLP-1 Pill Explained
Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist. This clarifier explains why people confuse it with peptide GLP-1 drugs and how FDA-approved Foundayo differs from research peptides.
Read articlePeptide Therapy Explained: What Clinics Mean, What’s Evidence-Based, and What’s Marketing
A cautious, evidence-aware guide to what peptide therapy means in clinics and marketing, how approved medicines differ from research compounds, and what questions to ask before trusting a claim.
Read articleBPC-157 and TB-500 Together: Evidence, Claims, and What’s Still Speculative
An evidence-aware guide to why BPC-157 and TB-500 are often discussed together, what mechanisms are claimed, what evidence exists separately versus as a combination, and where online recovery claims outrun the data.
Read articlePeptide Side Effects: What's Known, What's Unknown, and What People Overstate
A cautious, evidence-aware guide to peptide side effects, long-term unknowns, online claims, and how to read safety discussions without mistaking anecdotes for proof.
Read articleBest Peptides for Recovery: Evidence-Aware Comparison
A cautious comparison of recovery-related peptides by evidence quality, uncertainty, and claim strength — not recommendations, protocols, or buying advice.
Read articleHow to Evaluate Peptide Claims Online
A practical framework for reading peptide claims online: how to separate human evidence from preclinical signals, spot hype, and avoid mistaking confident marketing for proof.
Read articleTB-500 Side Effects and Unknowns: What Safety Evidence Actually Shows
TB-500 is often discussed as a recovery peptide, but its human safety profile is still uncertain. Here is what is known, what is not known, and how to read side-effect claims carefully.
Read articleWhat Is TB-500? An Evidence-Aware Overview
An evidence-aware overview of TB-500, its relationship to thymosin beta-4, what it is commonly discussed for, and where the evidence remains limited.
Read articlePeptides for Recovery: What the Evidence Actually Supports
A pillar guide to peptides for recovery that separates healing, soreness, and injury-repair claims while showing what the evidence actually supports.
Read articleBPC-157 vs TB-500: What's the Difference, and Which Recovery Peptide Question Are You Actually Asking?
BPC-157 and TB-500 are often discussed together for healing and recovery, but they have different mechanism stories, different common use cases, and similarly limited human evidence.
Read articleQuick Facts
- Origin
- Synthetic peptide associated with thymosin beta-4 research and related fragment discussions
- Amino acids
- 43
- Category
- Healing & Tissue Repair
Mechanisms
- Associated with thymosin beta-4 biology and actin-related cellular processes
- Discussed for tissue repair, cell migration, and recovery-related mechanistic pathways
- Human recovery claims remain limited and should not be treated as established clinical outcomes